Peytant Solutions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Peytant Solutions is a clinical-stage medical device company targeting a significant unmet need in oncology supportive care: the management of malignant airway obstructions. Its lead product, the AMStent System, is a self-expanding nitinol stent uniquely covered with a decellularized human amniotic membrane (DCAM), designed to elicit a reduced inflammatory and fibrotic response compared to standard covered stents. The company, founded by medtech veterans, has generated positive pre-clinical data and is advancing toward clinical trials. Peytant operates in the large and growing interventional pulmonology market, where current stent options are associated with high complication rates that its technology aims to address.

Oncology Supportive CarePulmonology

Technology Platform

Proprietary platform utilizing decellularized human amniotic membrane (DCAM) as a biocompatible cover for implants. The DCAM is intended to modulate the foreign body response, reducing inflammation, fibrosis, and granuloma formation associated with permanent luminal devices like stents.

Opportunities

The primary opportunity lies in addressing the significant complications of current airway stents for cancer patients, targeting an estimated 93,000-112,000 new U.S.

patients annually.

A successful product could become the standard of care in interventional pulmonology.

The underlying DCAM platform technology also presents a long-term opportunity for expansion into other luminal disease markets (e.g., GI, biliary).

Risk Factors

Key risks include the failure of pre-clinical results to translate to human safety and efficacy, complex manufacturing and supply chain challenges for a biologically derived product, and the difficulty of driving market adoption against established competitors despite potential clinical superiority.

Regulatory hurdles and securing adequate reimbursement are additional significant risks.

Competitive Landscape

Peytant competes in the airway stent market dominated by large medtech companies like Boston Scientific (Ultraflex, WallFlex), Medtronic, and Merit Medical, which offer silicone and metallic covered stents. Its direct competition is these existing covered stents, which are associated with high complication rates. Peytant's differentiation is its biocompatible DCAM cover designed to reduce these complications. Other potential competitors include companies developing bioabsorbable or drug-eluting stents for airways.

More companies in Drug Delivery & Formulation →More companies in United States →